BeOne’s initial clinical results support planned late-stage studies

BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% of responses continuing at six months. Across the 94-patient study’s dose levels, 5.3% experienced Grade 3 or higher treatment-related adverse events. The company plans global registrational trials by the end of 2026.

BeOne also reported initial results for its CEA-targeting antibody-drug conjugate BG-C477 in lung cancer: 14 of 25 patients with high CEA expression responded, a 56% rate, within a 43-patient cohort. These results broaden the clinical evidence for its solid-tumor pipeline. Both programs remain investigational, with small early-stage datasets; the findings do not establish superiority to standard treatment or guarantee that planned late-stage development will succeed.

Sources:

• ir.beonemedicines.com
• sttinfo.fi